Navigation Links
GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
Date:3/15/2012

ts associated with both our internal research programs and funded programs. General and administrative expenses in the fourth quarter of 2011 increased 33% to $2.0 million from $1.5 million in the comparable period in 2010 primarily due to increased personnel and recruiting costs, partially offset by lower professional costs.

2012 GuidanceGenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky, commented, "For 2012, we anticipate our cash burn will average $2.0 million per quarter."

Conference Call Information GenVec will hold a conference call today at 10:00 a.m. EDT to discuss the Company's financial results and 2012 business outlook. To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 47684520. An audio replay of the conference call will be available starting at 1:00 p.m. EDT on March 15, 2012 through March 22, 2012. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 (international) and use access code 47684520.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, and click on "Investors and Media".

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infecti
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec President and Chief Executive Officer Announces Retirement
2. GenVec Achieves Second Milestone in Collaboration
3. GenVec to Present at the 2011 10th Annual BIO Investor Forum
4. GenVec Renews Stockholder Rights Plan
5. GenVec Reports First Quarter 2011 Financial Results
6. GenVec Regains Compliance with NASDAQ Listing Requirements
7. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
8. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
11. GenVec Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation ... Medtronic, Inc. (NYSE: MDT ) has ... Food and Drug Administration (FDA) for the use ... infusion system (including a newly developed catheter) for ... Injection delivered intravenously to patients with pulmonary arterial ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" ... its 2015 Annual Meeting of Stockholders on May 4, ... date for the Annual Meeting represents a change of ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... 18 International Group, Ltd.,(Bloomberg: BIG SP, Company ... Conformite Europeenne (CE) Mark approval for its,BioMatrix(R) drug-eluting ... European Union and the countries in Asia and ... drug-eluting stent system,developed internally by the Company, consists ...
... Growth driving second new office opening in North Carolina in last 12 ... ... PARK, N.C., Jan. 17 Quintiles,Transnational Corp. today announced that the global ... is an expansion of Quintiles, clinical research in pharmaceutical,and biotechnology development., ...
... WALDWICK, N.J., Jan. 17 NEXCORE Technology,Inc, a ... licensed all the intellectual property rights for the,development ... endoscopic,surgery. The new system provides significantly greater control ... The patents on the system are held by ...
Cached Biology Technology:Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 2Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 3Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 4Quintiles to Open Clinical Research Office in Wilmington, NC 2NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System 2
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... of Medical Toxicology (ACMT) have signed an agreement to collaborate ... (JMT), the official journal of the ACMT, beginning in ... of Pennsylvania Press. The Journal of Medical ... the science and practice of medical toxicology. The quarterly ...
... is a matter of debate. A high-profile study a few ... their carbon from trees and leaves, evidence for a very ... new research from the University of Washington shows this is ... diet for fish and other aquatic life, according to research ...
... presents strong evidence that the "synergistic" effect of early-life ... causes more harm to developing lungs than one or ... scientists at the University of Cincinnati (UC) College of ... levels of traffic-related particles and indoor endotoxin during early ...
Cached Biology News:Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2
Request Info...
Request Info...
... purification systems provide high speed purification of ... offer increased throughput and reproducible results. The ... mL and KingFisher 96, covering sample volumes ... consists of an instrument, specially designed plastics ...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Biology Products: